Depression is common in
schizophrenia and worsens its course. The role of
antidepressants for schizophrenic depression remains unclear. In this study, the efficacy of add-on
mirtazapine on depression in
schizophrenia was explored in a subsidiary arm of a recent randomized controlled trial. Patients (n = 41) with chronic but stable
schizophrenia and inadequate response to stable doses of different first-generation
antipsychotics were treated with add-on
mirtazapine 30 mg or placebo during a 6-week double-blind phase and with open-label add-on
mirtazapine during a 6-week extension phase. Efficacy measures were the Calgary Depression Scale for
Schizophrenia (CDSS) and the Positive and Negative Syndrome Scale depression item. During the double-blind phase, both measures' scores decreased significantly in the
mirtazapine group but not in the placebo group (for the CDSS, 52.0% vs 19.6%, respectively). During the open‐label phase, both groups demonstrated significant improvements. In between‐group comparison, a trend favoring
mirtazapine did not reach statistical significance. The changes in the CDSS correlated positively with those in the Positive and Negative Syndrome Scale negative, positive and total (sub)scales for mirtazapine‐treated patients during the double‐blind phase. Depressed patients with
schizophrenia may benefit from mirtazapine–first‐generation
antipsychotics combination, with no increased risk for
psychosis. However, more studies are needed.